Poor
Not Aligned
Patient Risk:
Low
Summary
Only the MTC/thyroid C-cell tumors–risk-related claim is supported by the provided prescribing information. All other listed claims are not supported, contradicted, or cannot be verified against the supplied label excerpts, which focus only on the boxed warning/contraindication/counseling for thyroid C-cell tumors.
Category Scores
Accurate Statements
In rodents, semaglutide causes thyroid C-cell tumors / MTC risk related claim (if framed as boxed warning and unknown human relevance).
Supported by Boxed Warning (Risk of Thyroid C-Cell Tumors) and Section 5.1, and includes counseling and contraindication basis (Section 4).
Unsupported Statements
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Not supported by the provided label excerpts (only boxed warning/contraindications/counseling for thyroid C-cell tumors were included).
Ozempic works by mimicking the action of a natural hormone in the body to help regulate blood sugar levels.
Not supported by the provided label excerpts.
Ozempic is typically prescribed for patients with type 2 diabetes who have not achieved adequate control with other medications.
Not supported by the provided label excerpts.
Common side effects of Ozempic include nausea and vomiting.
Not supported by the provided label excerpts (no adverse reactions section content for these symptoms was provided).
Common side effects of Ozempic include diarrhea.
Not supported by the provided label excerpts.
Common side effects of Ozempic include abdominal pain.
Not supported by the provided label excerpts.
Common side effects of Ozempic include injection site reactions.
Not supported by the provided label excerpts.
Ozempic is associated with an increased risk of pancreatitis.
Not supported by the provided label excerpts.
Prolonged use of GLP-1 receptor agonists like Ozempic can lead to adaptation and tolerance.
Not supported by the provided label excerpts.
Patients who used GLP-1 receptor agonists for more than 6 months experienced a significant reduction in side effects compared to those who used them for shorter periods.
Not supported by the provided label excerpts.
Ozempic's patent is set to expire in 2030.
Not supported by the provided label excerpts (and patent status is not addressed in the supplied sections).
Using Ozempic for prolonged periods requires monitoring patients for side effects.
Not supported by the provided label excerpts.
Regular check-ups with a healthcare provider can help identify potential issues early during prolonged Ozempic use.
Not supported by the provided label excerpts.
Patients should report potential Ozempic side effects to their healthcare provider promptly.
Not supported by the provided label excerpts.
Prolonged Ozempic use may reduce its side effects.
Not supported by the provided label excerpts.
Patients with a history of pancreatitis should avoid using Ozempic because it may increase the risk of pancreatitis.
Not supported by the provided label excerpts.
Ozempic is not recommended for use during pregnancy or breastfeeding because it may pose a risk to the fetus or baby.
Not supported by the provided label excerpts.
Patients should consult with a healthcare provider before stopping Ozempic because stopping can lead to a range of complications.
Not supported by the provided label excerpts.
Regular blood sugar monitoring is essential when using Ozempic.
Not supported by the provided label excerpts.
Monitoring blood sugar levels 1-2 times a day is recommended when using Ozempic.
Not supported by the provided label excerpts.
A healthcare provider may recommend switching to a different medication if a patient experiences side effects from Ozempic.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
The label-provided boxed warning/contraindication content includes specific MTC-risk counseling and symptom examples (neck mass, dysphagia, dyspnea, persistent hoarseness), and uncertainty regarding routine serum calcitonin/thyroid ultrasound screening value. These elements were not captured by the provided claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-supported safety-related claim in the provided list is the existence of the boxed warning regarding thyroid C-cell tumors/MTC risk. However, numerous other safety-related and monitoring-related assertions were included without support from the supplied label excerpts, preventing on-label verification for those statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the FDA-approved prescribing information excerpts provided in the prompt; only the thyroid C-cell tumors/MTC risk boxed-warning/contraindication-related material is aligned.
Suggested Improvement
Restrict claims to the content present in the supplied label excerpts (Boxed Warning/Section 5.1/Section 4/Section 17 for thyroid C-cell tumors risk and counseling). Remove or re-verify all other claims (indication, dosing, adverse reactions, pancreatitis risk, pregnancy/breastfeeding, monitoring frequency, and patent status) against the specific corresponding FDA label sections.